Evidence map›Paper›PMID 35986402›Full record

ArticleJournal of experimental & clinical cancer research : CR2022

Transfection with Plasmid-Encoding lncRNA-SLERCC nanoparticle-mediated delivery suppressed tumor progression in renal cell carcinoma.

Weipu Mao, Keyi Wang, Wentao Zhang, Shuqiu Chen, Jinbo Xie, Zongtai Zheng, Xue Li, Ning Zhang, Yuanyuan Zhang, Haimin Zhang and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Integrative bioinformatics andOncology research · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Weipu Mao *Department of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China.
Keyi Wang *Department of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China.
Wentao Zhang *Department of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China.
Shuqiu Chen *Department of Urology, Affiliated Zhongda Hospital of Southeast University, No. 87 Dingjiaqiao, Hunan Road, Gulou District, Nanjing, 210009, P. R. China.
Jinbo Xie *Department of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China.
Zongtai Zheng *Department of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China.
Xue LiDepartment of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P. R. China.
Ning ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Yuanyuan ZhangInstitute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA.
Haimin ZhangDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China.
Bo PengDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China.
Xudong YaoDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China.
Jianping CheDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China. chejianping77@126.com.
Junhua ZhengState Key Laboratory of Oncogenes and Related Genes, Department of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China. zhengjh0471@sina.com.
Ming ChenDepartment of Urology, Affiliated Zhongda Hospital of Southeast University, No. 87 Dingjiaqiao, Hunan Road, Gulou District, Nanjing, 210009, P. R. China. mingchenseu@126.com.
Wei LiDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, No. 301, Yanchang Road, Jing'an District, Shanghai, 200072, P. R. China. weili06@tongji.edu.cn.ORCID http://orcid.org/0000-0001-6728-1300
Tongji University · CNZhongda Hospital Southeast University · CNCapital Medical University · CNHarvard University · USShanghai Jiao Tong University · CNWake Forest University · US

Funding

Fundamental Research Funds for the Central Universities 2016KJ045Innovative Team of Jiangsu Province 2017ZXKJQW07National Natural Science Foundation of China 81602469National Natural Science Foundation of China 82070773Natural Science Foundation of Shanghai Science and Technology Innovation Action Plan 20ZR1443000Pujiang Talents Plan 20PJ1412400Research Project Funding of Shanghai Health and Family Planning Commission 20164Y0093The National Key Research and Development Program of China SQ2017YFSF090096
6 · The paper itself

Abstract

backgroundThe accumulating evidence confirms that long non-coding RNAs (lncRNAs) play a critical regulatory role in the progression of renal cell carcinoma (RCC). But, the application of lncRNAs in gene therapy remains scarce. Here, we investigated the efficacy of a delivery system by introducing the plasmid-encoding tumor suppressor lncRNA-SLERCC (SLERCC) in RCC cells.

methodsWe performed lncRNAs expression profiling in paired cancer and normal tissues through microarray and validated in our clinical data and TCGA dataset. The Plasmid-SLERCC@PDA@MUC12 nanoparticles (PSPM-NPs) were tested in vivo and in vitro, including cellular uptake, entry, CCK-8 assay, tumor growth inhibition, histological assessment, and safety evaluations. Furthermore, experiments with nude mice xenografts model were performed to evaluate the therapeutic effect of PSPM-NPs nanotherapeutic system specific to the SLERCC.

resultsWe found that the expression of SLERCC was downregulated in RCC tissues, and exogenous upregulation of SLERCC could suppress metastasis of RCC cells. Furthermore, high expression DNMT3A was recruited at the SLERCC promoter, which induced aberrant hypermethylation, eventually leading to downregulation of SLERCC expression in RCC. Mechanistically, SLERCC could directly bind to UPF1 and exert tumor-suppressive effects through the Wnt/β-catenin signaling pathway, thereby inhibiting progression and metastasis in RCC. Subsequently, the PSPM-NPs nanotherapeutic system can effectively inhibit the growth of RCC metastases in vivo.

conclusionsOur findings suggested that SLERCC is a promising therapeutic target and that plasmid-encapsulated nanomaterials targeting transmembrane metastasis markers may open a new avenue for the treatment in RCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNanoparticlesRNA, Long NoncodingAnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceMice, NudePlasmidsRNA HelicasesTrans-ActivatorsTransfectionRNA HelicasesRNA, Long NoncodingTrans-ActivatorsUPF1 protein, humanGene therapylncRNA-SLERCCNanoparticlesRenal cell carcinomaTumor suppressor

Identifiers

PMID35986402
PMCPMC9389749
OpenAlexW4292854306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.